Zepbound shortage could be around the corner

Eli Lilly's CEO said supply of Zepbound, the drugmaker's new weight loss drug, might not meet 2024 demand.

After the drug was approved in November, the company sold 25,000 new prescriptions of Zepbound (tirzepatide) each week in December, Eli Lilly CEO David Ricks exclusively told Reuters.